{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:48:54Z","timestamp":1793134134093,"version":"4.5.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100021671","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021671","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA249016"],"award-info":[{"award-number":["R01CA249016"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ongoing active monitoring (AM) trials for women with ductal carcinoma in situ (DCIS) are investigating the safety and efficacy of monitoring DCIS lesions vs the current standard of care (surgical treatment). The frequency of upgrade in women undergoing AM for DCIS remains unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the frequency of upgrade of DCIS at core-needle biopsy to invasive carcinoma at surgical excision among women who meet eligibility criteria for AM trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective review between 2010 and 2023 was performed of women at an National Cancer Institute\u2013designated comprehensive cancer center with a diagnosis of DCIS at core-needle biopsy who underwent subsequent surgical excision. Medical records were reviewed for clinical presentation, imaging findings, core biopsy, and final surgical pathology. Each patient was evaluated for AM trial eligibility based on published criteria for the LORD, LORIS, and COMET trials. Fisher\u2019s exact test compared proportions, with a P-value &amp;lt;.05 considered statistically significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 264 women, 10\/264 (3.8%) were eligible for the LORD trial, 24\/264 (9.1%) for the LORIS trial, and 64\/264 (24.2%) for the COMET trial. Invasive carcinoma was found at surgical excision in 1\/10 (10%) patients eligible for the LORD trial, 2\/24 (8.3%) for the LORIS trial, and 9\/64 (14.1%) for the COMET trial. All occult invasive carcinomas detected at surgical excision in trial-eligible patients were node-negative, with a median size of invasive cancer measuring 3.5 mm (interquartile range, 1-7 mm).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A subset of women who meet eligibility criteria for DCIS AM trials are at risk for occult invasive carcinoma, with frequency of upgrade ranging from 8% to 14%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Impact<\/jats:title>\n                    <jats:p>More precise criteria and predictive biomarkers are needed to better stratify DCIS lesions and exclude women harboring invasive carcinomas from AM regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jbi\/wbaf085","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T12:43:22Z","timestamp":1769690602000},"page":"387-394","source":"Crossref","is-referenced-by-count":1,"title":["Ductal Carcinoma In Situ Active Monitoring Trials: Do Eligibility Criteria Identify Patients at Low Risk for Upgrade to Invasive Carcinoma?"],"prefix":"10.1093","volume":"8","author":[{"given":"Dana K","family":"Ataya","sequence":"first","affiliation":[{"name":"Division of Breast Imaging. Department of Diagnostic Imaging and Interventional Radiology, H. Lee Moffitt Cancer Center and Research Institute , Tampa, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K Ruwani M","family":"Fernando","sequence":"additional","affiliation":[{"name":"Department of Machine Learning, H. Lee Moffitt Cancer Center and Research Institute , Tampa FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Brainerd","sequence":"additional","affiliation":[{"name":"Non-Therapeutic Research Office, H. Lee Moffitt Cancer Center and Research Institute , Tampa FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yarelis","family":"De La Cruz","sequence":"additional","affiliation":[{"name":"Non-Therapeutic Research Office, H. Lee Moffitt Cancer Center and Research Institute , Tampa FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Abdalah","sequence":"additional","affiliation":[{"name":"Quantitative Imaging Core, H. Lee Moffitt Cancer Center and Research Institute , Tampa FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olya","family":"Stringfield","sequence":"additional","affiliation":[{"name":"Quantitative Imaging Core, H. Lee Moffitt Cancer Center and Research Institute , Tampa FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaheh","family":"Sobhani","sequence":"additional","affiliation":[{"name":"Department of Machine Learning, H. Lee Moffitt Cancer Center and Research Institute , Tampa FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8893-7687","authenticated-orcid":false,"given":"Natarajan","family":"Raghunand","sequence":"additional","affiliation":[{"name":"Quantitative Imaging Core, H. Lee Moffitt Cancer Center and Research Institute , Tampa FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn","family":"Bui","sequence":"additional","affiliation":[{"name":"Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute , Tampa, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6023-1132","authenticated-orcid":false,"given":"Issam","family":"El Naqa","sequence":"additional","affiliation":[{"name":"Department of Machine Learning, H. Lee Moffitt Cancer Center and Research Institute , Tampa FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany Lynn","family":"Niell","sequence":"additional","affiliation":[{"name":"Division of Breast Imaging. Department of Diagnostic Imaging and Interventional Radiology, H. Lee Moffitt Cancer Center and Research Institute , Tampa, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"issue":"3","key":"2026072806013856700_wbaf085-B1","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/jbi\/wbz039","article-title":"Ductal carcinoma in situ: current concepts in biology, imaging, and treatment","volume":"1","author":"Shehata","year":"2019","journal-title":"J Breast Imaging"},{"issue":"12","key":"2026072806013856700_wbaf085-B2","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1245\/s10434-017-6018-9","article-title":"Surgical upstaging rates for vacuum assisted biopsy proven DCIS: implications for active surveillance trials","volume":"24","author":"Grimm","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"2026072806013856700_wbaf085-B3","doi-asserted-by":"publisher","first-page":"4459","DOI":"10.1245\/s10434-020-08576-6","article-title":"Do eligibility criteria for ductal carcinoma in situ (DCIS) active surveillance trials identify patients at low risk for upgrade to invasive carcinoma?","volume":"27","author":"Oseni","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"2026072806013856700_wbaf085-B4"},{"key":"2026072806013856700_wbaf085-B5"},{"key":"2026072806013856700_wbaf085-B6"},{"key":"2026072806013856700_wbaf085-B7"},{"key":"2026072806013856700_wbaf085-B8"},{"issue":"5","key":"2026072806013856700_wbaf085-B9","doi-asserted-by":"publisher","first-page":"e230348","DOI":"10.1148\/ryai.230348","article-title":"Presurgical upgrade prediction of DCIS to invasive ductal carcinoma using time-dependent deep learning models with DCE MRI","volume":"6","author":"Mayfield","year":"2024","journal-title":"Radiol Artif Intell"},{"issue":"1","key":"2026072806013856700_wbaf085-B10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1148\/radiol.11102368","article-title":"Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer","volume":"260","author":"Brennan","year":"2011","journal-title":"Radiology"},{"issue":"11","key":"2026072806013856700_wbaf085-B11","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1245\/s10434-016-5268-2","article-title":"Do LORIS trial eligibility criteria identify a ductal carcinoma in situ patient population at low risk of upgrade to invasive carcinoma?","volume":"23","author":"Pilewskie","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"2026072806013856700_wbaf085-B12","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.5858\/arpa.2017-0268-OA","article-title":"Feasibility of the less is more approach in treating low-risk ductal carcinoma in situ diagnosed on core needle biopsy: ten-year review of ductal carcinoma in situ upgraded to invasion at surgery","volume":"142","author":"Podoll","year":"2018","journal-title":"Arch Pathol Lab Med"},{"issue":"10","key":"2026072806013856700_wbaf085-B13","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1093\/jnci\/djt067","article-title":"A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast","volume":"105","author":"Solin","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"2026072806013856700_wbaf085-B14","doi-asserted-by":"publisher","first-page":"5895","DOI":"10.1158\/1078-0432.CCR-18-0842","article-title":"A biological signature for breast ductal carcinoma in situ to predict radiotherapy benefit and assess recurrence risk","volume":"24","author":"Bremer","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2026072806013856700_wbaf085-B15","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/jamaoncol.2015.2510","article-title":"Breast cancer mortality after a diagnosis of ductal carcinoma in situ","volume":"1","author":"Narod","year":"2015","journal-title":"JAMA Oncol"},{"issue":"5","key":"2026072806013856700_wbaf085-B16","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.ajpath.2018.08.020","article-title":"Ductal carcinoma in situ biomarkers in a precision medicine era: current and future molecular-based testing","volume":"189","author":"Shee","year":"2019","journal-title":"Am J Pathol"}],"container-title":["Journal of Breast Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbi\/article-pdf\/8\/4\/387\/67209694\/wbaf085.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbi\/article-pdf\/8\/4\/387\/67209694\/wbaf085.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T10:01:46Z","timestamp":1785232906000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbi\/article\/8\/4\/387\/8504147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":16,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,3,3]]},"published-print":{"date-parts":[[2026,7,28]]}},"URL":"https:\/\/doi.org\/10.1093\/jbi\/wbaf085","relation":{},"ISSN":["2631-6110","2631-6129"],"issn-type":[{"value":"2631-6110","type":"print"},{"value":"2631-6129","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,3,3]]}}}